Dashboard
Manage Tickers

EPRX


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
Eupraxia Pharmaceuticals Q3 EPS $(0.19) Be...
11/04/2025 21:43:33

eupraxia-reports-encouraging-safety-and-efficacy-data-from-eosinophilic-esophagitis-study
Eupraxia Reports Encouraging Safety And Ef...
09/30/2025 14:40:39

Eupraxia's Cohort 9 RESOLVE trial data showed durable remission, improved tissue health, and strong safety, supporting Phas...

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
09/29/2025 21:06:06

Gainers SciSparc (NASDAQ: SPRC) shares increased by 28.2% to $5.68 during Monday's after-market session. The company's...

Core News & Articles
Eupraxia Pharmaceuticals Reports Results W...
09/29/2025 21:03:34

Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/23/2025 12:09:16

Core News & Articles
Reported Earlier, Eupraxia Pharmaceuticals...
09/23/2025 06:08:54

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
09/22/2025 21:06:10

Core News & Articles
Eupraxia Pharmaceuticals Announces Propose...
09/22/2025 20:01:41

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechn...

Core News & Articles
HC Wainwright & Co. Reiterates Buy on Eupr...
08/20/2025 10:33:15

HC Wainwright & Co. analyst Brandon Folkes reiterates Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy and maintains $1...

Core News & Articles
Eupraxia Pharmaceuticals Q2 EPS $(0.26) Mi...
08/12/2025 22:03:27

Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.26) per share which missed the analyst consensus estima...

this-sarepta-therapeutics-analyst-begins-coverage-on-a-bearish-note-here-are-top-5-initiations-for-thursday
This Sarepta Therapeutics Analyst Begins C...
07/24/2025 12:46:26

Core News & Articles
Cantor Fitzgerald Initiates Coverage On Eu...
07/24/2025 11:08:36

Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Overweight rati...

Core News & Articles
Eupraxia Doses First Patient in Phase 2b P...
07/08/2025 11:05:11

why-venus-concept-shares-are-trading-higher-by-over-32-here-are-20-stocks-moving-premarket
Why Venus Concept Shares Are Trading Highe...
06/30/2025 10:39:53

Core News & Articles
This NRG Energy Analyst Begins Coverage On...
06/26/2025 12:39:02

Core News & Articles
HC Wainwright & Co. Initiates Coverage On ...
06/26/2025 11:33:09

HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy ratin...

Core News & Articles
Eupraxia Pharmaceuticals Q1 EPS $(0.21) Be...
05/06/2025 22:12:27

Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate...

Core News & Articles
Eupraxia Pharma Announces Treatment Outcom...
05/05/2025 11:04:59

At 9 months active drug continued to be released into the esophagus in patients at a rate similar to what was seen at the 3- an...

Core News & Articles
Eupraxia Pharmaceuticals Q4 Net Profit $(7...
03/20/2025 21:47:32

The Company anticipates that existing cash reserves, and anticipated proceeds from in-the-money warrants, will be sufficient to...

Core News & Articles
Eupraxia's EP-104GI Demonstrates Strong Sa...
02/25/2025 12:51:50

Histological scores and symptom scores continue to improve as EP-104GI dose, and area of esophageal coverage, increaseCohort 6 ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION